Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 305

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose With Reduced-Dose Neuraxis Irradiation

Thomas, Patrick R. M., Deutsch, Melvin, Kepner, James L., Boyett, James M., Krischer, Jeffrey, Aronin, Patricia, Albright, Leland, Allen, Jeffrey C., Packer, Roger J., Linggood, Rita, Mulhern, Raymond, Stehbens, James A., Langston, James, Stanley, Philip, Duffner, Patricia, Rorke, Lucy, Cherlow, Joel, Friedman, Henry S., Finlay, Jonathan L., Vietti, Teresa J., Kun, Larry E.·2000·Journal of Clinical Oncology

Abstract

PURPOSE: To evaluate prospectively the effects on survival, relapse-free survival, and patterns of relapse of reduced-dose (23.4 Gy in 13 fractions) compared with standard-dose (36 Gy in 20 fractions) neuraxis irradiation in patients 3 to 21 years of age with low-stage medulloblastoma, minimal postoperative residual disease, and no evidence of neuraxis disease. PATIENTS AND METHODS: The Pediatric Oncology Group and Children’s Cancer Group randomized 126 patients to the study. All patients received posterior fossa irradiation to a total dose of 54 Gy in addition to the neuraxis treatment. Patients were staged postoperatively with contrast-enhanced cranial computed tomography, myelography, and CSF cytology. Of the registered patients, 38 were ineligible. RESULTS: The planned interim analysis that resulted in closure of the protocol showed that patients randomized to the reduced neuraxis treatment had increased frequency of relapse. In the final analysis, eligible patients receiving standard-dose neuraxis irradiation had 67% event-free survival (EFS) at 5 years (SE = 7.4%), whereas eligible patients receiving reduced-dose neuraxis irradiation had 52% event-free survival at 5 years (SE = 7.7%) (P = .080). At 8 years, the respective EFS proportions were also 67% (SE = 8.8%) and 52% (SE = 11%) (P = .141). These data confirm the original one-sided conclusions but suggest that differences are less marked with time. CONCLUSION: Reduced-dose neuraxis irradiation (23.4 Gy) is associated with increased risk of early relapse, early isolated neuraxis relapse, and lower 5-year EFS and overall survival than standard irradiation (36 Gy). The 5-year EFS for patients receiving standard-dose irradiation is suboptimal, and improved techniques and/or therapies are needed to improve ultimate outcome. Chemotherapy may contribute to this improvement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2000.18.16.3004

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 305

Metadata

Authors
Thomas, P. R. M., Deutsch, M., Kepner, J. L., Boyett, J. M., Krischer, J., Aronin, P., Albright, L., Allen, J. C., Packer, R. J., Linggood, R., Mulhern, R., Stehbens, J. A., Langston, J., Stanley, P., Duffner, P., Rorke, L., Cherlow, J., Friedman, H. S., Finlay, J. L., Vietti, T. J., & Kun, L. E.
Venue
Journal of Clinical Oncology
Published
2000-08-16
Volume
18
Issue
16
Pages
3004-3011
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1778834185
Cited by
305
References
10
FWCI
5.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose With Reduced-Dose Neuraxis Irradiation. https://app.cochat.ai/papers/10.1200/jco.2000.18.16.3004
The paper
Thomas, P. R. M., Deutsch, M., Kepner, J. L., Boyett, J. M., Krischer, J., Aronin, P., Albright, L., Allen, J. C., Packer, R. J., Linggood, R., Mulhern, R., Stehbens, J. A., Langston, J., Stanley, P., Duffner, P., Rorke, L., Cherlow, J., Friedman, H. S., Finlay, J. L., . . . Kun, L. E. (2000). Low-Stage Medulloblastoma: Final Analysis of Trial Comparing Standard-Dose With Reduced-Dose Neuraxis Irradiation. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.16.3004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.